WNT5A and metastatic malignant neoplasm in the lymph nodes: Using this optimized IRS approach and adjusting for clinically relevant factors (sex of the patients, TNM stage, lymph node metastasis; Table S1), we performed a multivariate analysis of low-risk (high WNT5A expression) and high-risk (low WNT5A expression) patients (Figure 1D).